Exemestane - Page 3

Exemestane introduced under the name Aromasin is a strong steroidal suicide aromatase inhibitor developed by Pharmacia & Upjohn. It inhibits the enzyme that produces estrogen and has shown to lower estrogen lvl by the around 85 percent as medicine in studies. First approved by the FDA in 1999, it is used primarily in postmenopausal women with breast cancer whose disease has progressed following tamoxifen treatment. Exemestane has become quite popular among athletes, for its off label application in dealing with estrogen related side effect such, as gynecomastia (enlargement of male breast tissue) fat accumulation and water retention that may occur during the use of steroids. It is now available in more than thirty countries all around the world.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For more details consult with your doctor or healthcare professional.